SCHEMBL25333362

SCHEMBL25333362

CCOCCCn1c(=O)[nH]c2ccccc2c1=O

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
HPGD P15428 3/20 0.64
CYP1A2 P05177 1/20 0.62
MPO P05164 2/20 0.62
HSD17B10 Q99714 5/20 0.60
KDM4E B2RXH2 5/20 0.60
MAPK1 P28482 1/20 0.60
MAPT P10636 2/20 0.57
GLA P06280 1/20 0.56
QPCT Q16769 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
MAPK10 P53779 1/20 0.54
TP53 P04637 1/20 0.53
ADORA3 P0DMS8 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25335252 0.87 MPO (0.63) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL14560539 0.84 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL8652560 0.83 MPO (0.72) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL8692730 0.81 CYP1A2 (0.76) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL22716785 0.80 CYP1A2 (0.65) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL31189218 0.80 CYP1A2 (0.65) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL7654811 0.80 HSD17B10 (0.71) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL8987938 0.79 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL5112012 0.79 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2MPOHSD17B10
SCHEMBL10288922 0.78 MPO (0.92) ALDH1A1HPGDCYP1A2MPOHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12564547-B2 Compositions, formulations, and methods for skin treatment ODDITY LABS, LLC (US) 2026-03-03 US disclosed
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT ODDITY LABS, LLC 2023-08-03 US disclosed
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT ODDITY LABS, LLC 2023-08-03 US disclosed
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT ODDITY LABS, LLC 2023-08-03 US disclosed
WO-2023133240-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT REVELA, INC. (US) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT CUTA, COL14A1, DSG1 ALDH1A1 3302/4885HPGD 1792/4885CYP1A2 2664/4885
US-12564547-B2 Compositions, formulations, and methods for skin treatment MCOLN1, H1-0, APOL1 ALDH1A1 1590/4885HPGD 4173/4885CYP1A2 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.